These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3535845)

  • 1. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium carbonate as a phosphate binder. One year's experience.
    Kobrin SM; Epstein SE; Goldstein SJ; Kramer MS; Raja RM
    ASAIO Trans; 1987; 33(3):518-20. PubMed ID: 3314935
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium carbonate as a phosphate binder in hemodialysis patients.
    Taber TE; Hegemen TF; York S
    ASAIO Trans; 1986; 32(1):127-9. PubMed ID: 3778697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.
    Andreoli SP; Dunson JW; Bergstein JM
    Am J Kidney Dis; 1987 Mar; 9(3):206-10. PubMed ID: 3826069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 7. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis.
    Meyrier A; Marsac J; Richet G
    Kidney Int; 1973 Aug; 4(2):146-53. PubMed ID: 4744972
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 14. Alternative phosphate binders in dialysis patients: calcium carbonate.
    Slatopolsky E; Weerts C; Stokes T; Windus D; Delmez J
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):35-41. PubMed ID: 3602677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 16. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of calcium carbonate as an intestinal chelator of phosphorus].
    Bongiorno P; Caligaris F; Montalcini G; Biamino E; Imarisio P; Dagna L; Arnaud A
    Minerva Urol Nefrol; 1990; 42(1):55-7. PubMed ID: 2389224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.